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The following principles of appropriate antibiotic use for adults
with acute bronchitis apply to immunocompetent adults with-
out complicating comorbid conditions, such as chronic lung or
heart disease.
1. The evaluation of adults with an acute cough illness or a
presumptive diagnosis of uncomplicated acute bronchitis
should focus on ruling out serious illness, particularly pneumo-
nia. In healthy, nonelderly adults, pneumonia is uncommon in
the absence of vital sign abnormalities or asymmetrical lung
sounds, and chest radiography is usually not indicated. In
patients with cough lasting 3 weeks or longer, chest radiogra-
phy may be warranted in the absence of other known causes.
2. Routine antibiotic treatment of uncomplicated acute bron-
chitis is not recommended, regardless of duration of cough. If
pertussis infection is suspected (an unusual circumstance), a
diagnostic test should be performed and antimicrobial therapy
initiated.
3. Patient satisfaction with care for acute bronchitis depends
most on physician–patient communication rather than on anti-
biotic treatment.
[Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM,
Hoffman JR, Sande MA. Principles of appropriate antibiotic use
for treatment of uncomplicated acute bronchitis: background.
Ann Emerg Med. June 2001;37:720-727.]
The term “acute bronchitis” usually designates an acute
respiratory tract infection in which cough, with or with-
out phlegm, is a predominant feature.1,2 In the United
States, about 5% of adults self-report an episode of acute
bronchitis each year, and up to 90% of these persons seek
medical attention.3-5 In 1997, adults in the United States
made more than 10 million office visits for bronchitis.6
As a result, acute bronchitis consistently ranks among the
10 conditions that account for most ambulatory office
visits to U.S. physicians.6-11
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Most cases of acute bronchitis occur in otherwise
healthy adults, in whom this acute cough illness can be
called “uncomplicated acute bronchitis”; these principles
are intended to apply to such patients. The evaluation and
management of acute cough illness in patients with
underlying chronic obstructive pulmonary disease, con-
gestive heart failure, or immunosuppression must be tai-
lored in light of the patient’s comorbid condition and is
outside the scope of this discussion. The background of,
rationale for, and methods used to develop these princi-
ples are published separately.12
P R I N C I P L E S
1.0 Evaluation of Acute Cough Illness
Principle 1. The evaluation of adults with an acute cough, illness,
or a presumptive diagnosis of uncomplicated acute bronchitis should
focus on ruling out serious illness, particularly pneumonia.
1.1 A wide variety of infections and inflammatory dis-
orders can lead to an acute cough illness. The American
College of Chest Physicians defines acute cough illness, in
contrast to chronic or persistent cough, as lasting less
than 3 weeks.13 Acute upper respiratory tract infection
accounted for approximately 70% of primary diagnoses
in adults presenting for an ambulatory office visit with a
chief symptom of cough.14 Asthma and pneumonia were
the next most common diagnoses, assigned to 6% and 5%
of patients, respectively. The predominance of cough and
accompanying clinical features suggestive of an acute
upper respiratory tract infection, such as sore throat or
rhinorrhea, is usually used to distinguish bronchitis from
other acute upper respiratory tract infections.1 As one
might expect, clinicians are inconsistent in assigning each
diagnosis.2 For example, some clinicians diagnose acute
bronchitis only when productive cough is present; others
insist on the presence of purulent sputum.
1.2 Previously undiagnosed asthma is a consideration
in patients presenting with an acute cough illness. How-
ever, in the setting of acute cough ( <2 to 3 weeks’ dura-
tion), the diagnosis of asthma is difficult to establish
because many patients with acute bronchitis will have
transient bronchial hyperresponsiveness (and abnormal
results on spirometry). No guidelines have been estab-
lished for distinguishing transient from chronic bronchial
hyperresponsiveness, and long-term follow-up studies
suggest that abnormalities on pulmonary function testing
in patients with uncomplicated acute bronchitis typically
resolve after 2 to 3 weeks, although they may last as long
as 2 months.15-17 The diagnosis of cough-variant asthma,
in contrast, is generally reserved for patients with persis-
tent cough ( >2 to 3 weeks’ duration), lack of wheezing,
and (usually) normal results on pulmonary function
tests.18,19 Cough-variant asthma should be suspected in
adults with persistent cough that worsens at night or after
exposure to cold or exercise; the diagnosis relies on im-
provement of symptoms with bronchodilator treatment
or a positive result on a methacholine challenge test.
Therefore, in the absence of severe airflow obstruction, it
is prudent to limit evaluation for possible chronic asthma
or cough-variant asthma to patients with cough illness
lasting longer than 3 weeks.
1.3 When evaluating an otherwise healthy adult with
uncomplicated acute cough illness, the primary diagnos-
tic objective should be to exclude the presence of pneu-
monia. Four prospective studies (1984 to 1990) examined
the accuracy of patient history and physical examination
for diagnosing radiographic pneumonia in adults with
acute respiratory illness in outpatient and emergency
department settings, and a clinical decision tool to deter-
mine the need for radiography was developed.20-23 A
subsequent validation study done by an independent
group of investigators found that the specificity (about
67%) but not the sensitivity (about 75%) of these predic-
tion rules for detecting radiographic pneumonia exceeded
that of physician judgment (specificity, 58%).24 An
evidence- and quality-based review of these studies25
concluded that the absence of abnormalities in vital signs
(heart rate ≥100 beats/min, respiratory rate ≥24 breaths/
min, or oral temperature ≥38°C) and chest examination
(focal consolidation—for example, rales, egophony, or
fremitus) sufficiently reduces the likelihood of pneumo-
nia to the point where further diagnostic testing is usually
not necessary [A]. (Letters in square brackets are evidence
ratings. See the background document in this issue12 for
explanation.)
Notably absent from all of the rules is the presence of
purulent sputum. Many patients and physicians seem to
believe that purulent sputum signifies that a bacterial
infection is present and antibiotic therapy is indicated.26-28
Purulence primarily occurs when inflammatory cells or
sloughed mucosal epithelial cells are present, and it can
result from either viral or bacterial infection.29,30
1.4 Specific patient and epidemiologic circumstances
should be taken into account before this recommenda-
tion is applied. Although all of the studies on which this
recommendation is based included elderly persons and
patients with chronic lung disease, subgroup analyses
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serology, or polymerase chain reaction. Specific viruses
most frequently associated with acute bronchitis include
those that produce primarily lower respiratory tract dis-
ease (influenza B, influenza A, parainfluenza 3, and respi-
ratory syncytial virus), as well as viruses that more com-
monly produce upper respiratory tract symptoms (corona
virus, adenovirus, and rhinoviruses). Unless bacterial
superinfection is present (defined as pneumonia with an
infiltrate on chest radiography), antibiotic treatment does
not affect the clinical course of viral respiratory infections.
2.2 To date, only Bordetella pertussis, Mycoplasma pneu-
moniae, and C. pneumoniae (TWAR) have been established
as nonviral causes of uncomplicated acute bronchitis in
adults. As a group, these agents are associated with 5% to
10% of all cases of uncomplicated acute bronchitis in
adults. They are recovered more frequently (10% to 20%
of cases) in studies of adults with chronic or persistent
cough.39-41 The diagnoses in these studies are frequently
based on serologic conversion, an event that can also
occur in asymptomatic persons and may not be related to
the clinical illness in question. More recent studies using
polymerase chain reaction have reported similar frequen-
cies of recovery of these agents in adults with acute bron-
chitis. No evidence indicates that Streptococcus pneumo-
niae, Haemophilus influenzae, or Moraxella catarrhalis
produces acute bronchitis in adults without underlying
lung disease. Studies reporting an association between
these encapsulated bacteria and acute bronchitis have
failed to distinguish between colonization and acute
infection. Since Gram stain and culture of sputum do not
reliably detect M. pneumoniae, C. pneumoniae, or B. pertus-
sis, these tests are not recommended in the evaluation of
patients with uncomplicated acute bronchitis.
3.0 Treatment of Uncomplicated Acute Bronchitis
Principle  2. Routine antibiotic treatment of uncomplicated acute
bronchitis is not recommended, regardless of duration of cough [A].
3.1 On the basis of the microbiology of acute bronchi-
tis, it should not be surprising that randomized, placebo-
controlled trials have failed to support a role for antibiotic
treatment of uncomplicated acute bronchitis (Table).42-50
By the mid-1990s, published reviews of randomized,
placebo-controlled trials51,52 had concluded that routine
antibiotic treatment of acute bronchitis does not have a
consistent impact on duration or severity of illness or on
potential complications, such as development of pneu-
monia. Consistent with these conclusions, the U.S. Food
and Drug Administration removed uncomplicated acute
bronchitis (or “secondary bacterial infections of acute
bronchitis”) as an indication for randomized, controlled
trials of antimicrobial therapy in 1998. Since then, three
were not performed; a high index of suspicion for pneu-
monia therefore remains warranted in these patient
groups, given the increased likelihood for atypical disease
presentation.31,32 Conversely, even when vital sign
abnormalities are detected in the absence of chest auscul-
tatory findings, chest radiography may not be indicated
in patients with other clinical features consistent with a
viral illness (such as influenza, parainfluenza, or respira-
tory syncytial virus) or features that are inconsistent with
pneumonia (such as streptococcal pharyngitis or chronic
sinusitis). Cough lasting longer than 3 weeks exceeds the
case definition for acute bronchitis; such patients should
be considered to have persistent cough or chronic cough
illness. Irwin and colleagues have developed a well-
defined approach to the adult with persistent cough [D].13
2.0 Microbiology of Uncomplicated Acute Bronchitis
The vast majority of cases ( ≥90%) of uncomplicated
acute bronchitis have a nonbacterial cause. We reviewed
the MEDLINE database (1966 to October 1999) by using
Medical Subject Headings and keyword searches that
included microbiology and bronchitis and analyzed refer-
ences from review articles and chapters in textbooks on
infectious disease to identify studies of the microbiology
of acute bronchitis. We excluded studies involving
patients with chronic lung disease, malignant conditions,
or immunosuppression, as well as those conducted dur-
ing confirmed outbreaks of a pathogen (for example, a
Chlamydia pneumoniae outbreak at a single university).
We limited our selection to English-language studies of
consecutive, unselected adolescents or adults enrolled in
nonreferral, ambulatory settings. In the mid-1980s, it
was established that a specific species of C. pneumoniae
(TWAR) could cause uncomplicated acute bronchitis.
Therefore, estimates of the proportion of cases with a
potential bacterial cause are limited to studies published
since this discovery.33,34
2.1 As in community-acquired pneumonia, microbio-
logical study of uncomplicated acute bronchitis identifies
a pathogen in the minority of cases, ranging from 16% to
40%.17,35-38 This variability is most likely due to the epi-
demic nature of agents that produce uncomplicated acute
bronchitis and limitations in viral and bacterial identifi-
cation techniques. Noninfectious causes of uncompli-
cated acute bronchitis, such as occult asthma exacerba-
tion or toxic fume inhalation, should also be considered,
although the prevalence of these conditions in adults with
acute cough illness has not been well studied. In epidemi-
ologic studies, respiratory viruses, particularly influenza,
appear to cause the large majority of cases of uncompli-
cated acute bronchitis according to culture, antibody
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Table.
Randomized, placebo-controlled trials of antibiotic treatment in adults with acute bronchitis.*
Study, Year
(Reference) Location Participants Interventions Outcomes
Stott and West, United Kingdom Persons >14 years of age with Doxycycline, 200 mg on day 1, For average days of daytime cough, yellow spit, “off color”
1976 (42) cough producing purulent then 100 mg/d for 9 days spit, nighttime cough, runny nose, clear spit, sore throat,
sputum for ≤1 week general aches and pains, headache, vomiting, and days of
missed work, differences between placebo (n = 130) and
antibiotic (n = 104) groups were nonsignificant; fewer
patients in antibiotic group had runny nose at day 7 (P < .05);
no difference in cough, purulent sputum, feeling unwell, and
days of missed work; no difference among smokers; smaller
proportion of patients with upper respiratory tract infection
in doxycycline (13%) vs. placebo group (25%) at 6 months;
no difference in subsequent lower respiratory tract
infections, other infections, or asthma
Franks and Gleiner, Rochester, New York Persons >14 years of age with Trimethoprim-sulfamethoxazole “Mean” number of patients with cough over 7 days, 99%
1984 (47) productive cough for (160 mg/800 mg) twice daily (n = 29) in placebo group vs. 93% in the antibiotic group
<15 days for 7 days (n = 25) (1-tailed P = .05); “mean” number of patients
recording night cough over 7 days, 84% vs. 56% (P = .003);
mean temperature, 37.3°C vs. 36.9°C; no difference in
cough frequency, cough amount, activity level, time to 
return to work, and use of other symptomatic medications
Williamson, Columbia, Missouri Persons 18–65 years of age Doxycycline, 100 mg twice Average duration of cough, 18 days in placebo group (n = 32)
1984 (44) with productive cough of any daily on day 1, then 100 mg/d vs. 20 days in antibiotic group (n = 37); difference in absence
duration; patients with oral for 7 days from work, 0.6 days vs. 1.5 days (P = .03); days of fever, days
temperature >39.5°C of purulent sputum mean symptom scores, antibiotic treat-
excluded ment at follow-up visit, and unscheduled return visits not
significantly different between groups 
Brickfield et al, Fairfax, Virginia Persons 18–65 years of age Erythromycin, 333 mg three Mean daily symptom scores for each of 7 days favored placebo
1986 (46) with productive cough illness times daily for 7 days (n = 25) for 4 comparisons and antibiotic (n = 27) for 6 com-
for ≤2 weeks parisons; at P = .05, one would expect 7 statistically signi-
ficant differences by chance alone
Dunlay et al, Michigan Persons ≥18 years of age with Erythromycin, 333 mg three Mean total symptom score over 10 days, about 2.25 in placebo
1987 (48) productive cough of any times daily for 10 days group (n = 24) vs. 1.8 in antibiotic group (n = 24) (P < .01);
duration proportion of patients with congestion at day 10, 75% vs.
38%; proportion of patients taking cough or cold medicines 
at day 10, 38% vs. 3% (P < .05); no difference between 
groups for day cough, night cough, productive cough, sore
throat, feeling poor or unable to work or carry out daily
routine at day 10; no differences among smokers
Scherl et al, Kentucky Persons >12 years of age with Doxycycline, 100 mg twice Mean (± SD) duration of cough, 10.8 ± 1.2 days in placebo
1987 (50) self-described cough daily on day 1, then 100 mg/d group vs. 9.4 ± 1.5 days in antibiotic group; mean duration
producing purulent sputum for 7 days of sputum, 10.4 ± 1.4 days vs. 8.5 ± 1.5 days 
for <2 weeks
Verheij et al, Leiden, The Netherlands Persons ≥18 years of age Doxycycline, 200 mg on day 1, Proportion of patients with “frequent” daytime cough, 39%
1994 (45) then 100 mg/d for 10 days in placebo (n = 69) group vs. 21% in antibiotic group (n =
71) (P < .05); no difference in proportion with nighttime
cough or productive cough; proportion of patients who felt
ill, 19% vs. 35%, but no difference in proportion who
looked ill; no difference in proportion of patients in whom
clinical condition improved; mean duration of daytime
cough, 6.2 days vs. 4.7 days (P < .01), but no difference in
mean nighttime cough, productive cough, feeling ill, or
impaired daily activities; subgroup analyses among
patients ≥55 years of age or older and those who had very
frequent cough and felt ill showed statistically significant
differences; at study entry, a greater proportion of patients
in the antibiotic group felt ill 
King et al, 1996 (43) North Carolina Persons ≥8 years of age with Erythromycin, 250 mg/d for Self-reported cough frequency, general feeling of well-being
productive cough for ≤2 10 days chest congestion, and use of cough medicines did not differ
weeks between placebo (n = 42) and antibiotic (n = 49) groups;
fewer days of work lost in antibiotic group (0.81 days vs.
2.16 days (P < .02); no differences among those with and
without serologic evidence of mycoplasma infection
*All studies excluded patients with chronic disease, clinical evidence of pneumonia, pregnancy, recent antibiotic use, and history of hypersensitivity to the antibiotic to be used.
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to decrease shedding of the pathogen and spread of dis-
ease, since antibiotic treatment does not appear to hasten
resolution of symptoms if it is initiated 7 to 10 days after
onset of illness.57-59 Because of the public health implica-
tions of pertussis, antibiotic treatment of suspected per-
tussis should always be accompanied by a diagnostic test.
Diagnostic tests for pertussis are not routinely available;
one could inquire at local or state health departments or
academic medical centers for further assistance.
3.3 Influenza
Because influenza is the most common pathogen iso-
lated in patients with uncomplicated acute bronchitis, it
is worthwhile discussing recent advances in diagnosis
and treatment of influenza. Although amantadine and
rimantidine have been available for more than 30 years,60,61
the recent development and direct-to-consumer market-
ing of neuraminidase inhibitor therapy has generated
immense public and physician interest in pharmacologic
treatment of influenza.62 A Cochrane Collaboration–
sponsored systematic review of neuraminidase inhibitors
for the treatment of influenza in healthy adults was recently
performed.63 Inhaled (zanamivir) and oral (oseltamivir)
formulations of neuraminidase inhibitors have demon-
strated some efficacy in reducing illness duration64-66 in
adults with naturally acquired influenza A and B if treat-
ment begins within 48 hours of symptom onset.
The major clinical advantage of neuraminidase inhibi-
tor therapy relates to activity against influenza A and B;
amantadine and rimantidine, in contrast, have activity
only against influenza A. The relative proportion of cases
due to each type of influenza varies substantially from
year to year. In the 1999–2000 influenza season, 99% of
influenza cases from surveillance facilities in the United
States were due to influenza A. All drugs appear to have a
similar impact on influenzal illness: about 1 less day of ill-
ness, and about a half-day quicker return to normal activ-
ities. On the basis of the Cochrane Collaboration’s calcu-
lations, adverse effects are modestly more frequent with
rimantadine (in about 32% of patients; most cases are
related to the central nervous system) than oral neura-
minidase inhibitor (in about 24% of patients; most cases
are gastrointestinal) or placebo (in about 19% of patients).
Neuraminadase inhibitors are likely to be much more
costly to health plans and patients than rimantadine,
although formularies are likely to vary considerably.
For any of these antiviral agents to be effective, influenza
must be diagnosed and therapy initiated within 48 hours
(preferably <30 hours) of symptom onset. During docu-
mented influenza outbreaks, the positive predictive value
of clinical diagnosis based on clinician judgment appears
meta-analyses have also been published.53-55 These
meta-analyses are plagued by lack of uniformity in out-
come measures used in each of the randomized, placebo-
controlled trials and by inclusion of poor-quality studies.
In one of the meta-analyses,54 no statistically significant
benefit of antibiotic treatment was observed when cough
duration was treated as a continuous variable. However,
when cough was treated as a dichotomous variable (pro-
portion of patients with cough at a follow-up visit), the
investigators reported a significant difference (relative
risk, 0.69 [95% CI, 0.49 to 0.98]). Another meta-analysis55
transformed heterogenous outcome measures to calcu-
late a “standardized effect size” and reported that antibi-
otic therapy decreases the duration of cough and sputum
by 0.5 day (over a 7-day period). The third meta-analy-
sis53 excluded three trials that were included in the previ-
ous meta-analyses on the basis of poor quality45 or lack of
information on loss to follow-up43,46; those investigators
reported no benefit of antibiotic treatment on cough
duration. All three meta-analyses reported no impact of
antibiotic treatment on duration of illness, limitation of
activity, or loss of work, and all concluded that routine
antibiotic treatment of acute bronchitis in adults is not
justified.
Identification of cases of bacterial or mycoplasma-
associated bronchitis might seem to be a reasonable strat-
egy for selecting patients in whom antimicrobial therapy
would be beneficial. However, studies to date have been
unable to distinguish bacterial bronchitis from viral bron-
chitis on clinical grounds. Furthermore, the single ran-
domized, placebo-controlled trial in which subgroup
analysis of patients with probable mycoplasma infection
(based on a single rapid serology test) was done did not
find a consistent benefit of antibiotic treatment. However,
the sample was fairly small (42 and 49 patients in the
placebo and treatment groups, respectively).43
3.2 The one uncommon circumstance for which evi-
dence supports antibiotic treatment of patients with
uncomplicated acute bronchitis is suspicion of pertussis.
Selected studies have recovered pertussis in up to 10% to
20% of patients with cough lasting longer than 2 to 3
weeks.39,40 Unfortunately, no clinical features allow clin-
icians to distinguish adults with persistent cough due to
pertussis, primarily because pertussis in adults with pre-
vious immunity does not lead to the classic features of
whooping cough seen in patients (usually children) with
primary infection.56 Therefore, clinicians should limit
suspicion and treatment of adult pertussis to adults with a
high probability of exposure to pertussis—for example,
during documented outbreaks. Antimicrobial therapy for
suspected pertussis in adults is recommended primarily
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to be good and to perform as well as available rapid diag-
nostic tests for influenza; reported sensitivities of these
tests range from 63% to 81%.67-69 Reports from the
Management of Influenza in the Southern Hemisphere
Trialists study, which evaluated neuraminidase treatment
of community-acquired influenza, suggest that clinical
diagnosis or suspicion of influenza is correct approxi-
mately 70% of the time during documented influenza
outbreaks.66 Although this study was not adequately
designed to evaluate the true sensitivity or specificity of
clinical diagnosis, which would have required measuring
the rate of influenza infection in patients in whom it was
not suspected, the findings probably accurately reflect
clinical practice. Accurate clinical diagnosis of influenza
outside the annual outbreak period is more difficult. As a
result, diagnostic testing for influenza outside outbreaks,
when suspected, may be considered for epidemiologic
purposes.
3.4 Symptomatic Therapy
What symptomatic therapy should we offer patients
seeking care for uncomplicated acute bronchitis? The
first task is to identify which symptoms are most bother-
some to the patient. In most cases, cough is the major
symptom for which patients seek relief. Randomized, con-
trolled trials have demonstrated a consistent benefit of
therapy with albuterol versus placebo for uncomplicated
acute bronchitis in reducing the duration and severity of
cough (in one study, the “placebo” was erythromycin).70-72
Approximately 50% fewer patients report the presence of
cough after 7 days of treatment. The efficacy of broncho-
dilators in patients with uncomplicated acute bronchitis
makes sense given the frequent finding of bronchial
hyperresponsiveness in these patients. The randomized,
placebo-controlled trials of albuterol have reported
mixed results in identification of subsets of patients most
likely to benefit from treatment; therefore, treatment
should be individualized in patients without clinical evi-
dence of bronchial hyperresponsiveness (such as wheez-
ing or bothersome cough).72
3.5 The literature evaluating the efficacy of antitussive
treatments is problematic because treatment benefit
appears to depend on the cause of the cough illness. Acute
or early cough due to colds or other viral upper respira-
tory tract infections does not appear to respond to dex-
tromethorphan or codeine, whereas chronic cough (dura-
tion >3 weeks), cough associated with underlying lung
disease, or experimentally induced cough seems to
respond to these two agents. In patients with uncompli-
cated acute bronchitis (in whom the average duration of
cough is 2 to 3 weeks), preparations containing dex-
tromethorphan or codeine probably have a modest effect
on severity and duration of cough. Although evidence
from randomized, placebo-controlled trials is lacking,
other low-cost and low-risk actions, such as elimination
of environmental cough triggers (for example, dust and
dander) and vaporized air treatments (particularly in
low-humidity environments, such as high altitude) are
also reasonable options, given the underlying pathophys-
iology of uncomplicated acute bronchitis.
Principle 3. Patient satisfaction with care for acute bronchitis
depends most on physician–patient communication rather than
whether an antibiotic is prescribed [B].
4.0 Clinicians caring for patients with uncomplicated
acute bronchitis should be encouraged to discuss the lack
of benefit of antibiotic treatment for uncomplicated acute
bronchitis and stop prescribing antibiotics for this condi-
tion as a standard of practice. Patients frequently expect
to receive antibiotics for uncomplicated acute bronchi-
tis5,73; however, this expectation appears to derive from
previous receipt of antibiotics for uncomplicated acute
bronchitis.5 Mounting evidence indicates that patient sat-
isfaction with the office encounter for uncomplicated
acute bronchitis does not depend on receipt of antibiotic
therapy but instead is related to the patient-centered
quality of the encounter (for example, believing that the
provider spent enough time and explained the illness and
treatment plan).73 A combined patient and physician
educational intervention that reduced antibiotic use for
acute bronchitis did not lead to greater utilization of ser-
vices (such as nonantibiotic prescriptions or return vis-
its),74 greater patient dissatisfaction, or longer duration
of illness.75 A recommended outline for discussing the
management of acute bronchitis with patients includes
the following steps.
1. Provide realistic expectations for the duration of the
patient’s cough, which will typically last 10 to 14 days
after the office visit.
2. Refer to the cough illness as a “chest cold” rather
than bronchitis.5 In a study of members of a commercial
managed care organization’s health plan, use of the term
“chest cold” was associated with much less frequent belief
that antibiotic therapy was necessary to get better.
3. Personalize the risk of unnecessary antibiotic use.
Inform patients that previous antibiotic use increases
their likelihood of carriage of and infection with antibiotic-
resistant bacteria, that antibiotics commonly have side
effects (gastrointestinal symptoms or alterations in taste,
for example), and that rare but serious adverse reactions
may occur, such as anaphylaxis.
4. Explain to patients why we need to be more selec-
tive in treating only those conditions for which a major
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